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ABSTRACT
Cat-scratch disease (CSD), caused by Bartonella henselae infection, can mimic malignancy and can
manifest atypically. Reliable serological testing is therefore of great clinical importance. The diagnostic
performance of immunoﬂuorescence assay (IFA) and ELISA was evaluated in a group of Dutch patients
with proven CSD (clinical diagnosis conﬁrmed by PCR). Sera of 51 CSD patients and 56 controls
(patients with similar symptoms, but who were B. henselae PCR-negative and had an alternative
conﬁrmed diagnosis) were tested for anti-B. henselae IgM and IgG by IFA and ELISA. A commercially
available IFA test for IgM had a sensitivity of 6%. In-house assays for IgM showed speciﬁcities of 93%
(IFA) and 91% (ELISA), but with low sensitivities (53% and 65%, respectively). With a speciﬁcity of
82% (IFA) and 91% (ELISA), in-house IgG testing showed a signiﬁcantly higher sensitivity in IFA (67%)
than in ELISA (28%, p <0.01). Sensitivity was higher for genotype I (38–75%) than for genotype II
(7–67%) infections, but this was only statistically signiﬁcant for IgG ELISA (p <0.05). In conclusion,
detection of IgM against B. henselae by in-house ELISA and IFA was highly speciﬁc for the diagnosis of
CSD. The high seroprevalence in healthy individuals limits the clinical value of IgG detection for
diagnosing CSD. Given the low sensitivity of the serological assays, negative serology does not rule out
CSD and warrants further investigation, including PCR. Adding locally isolated (e.g., genotype II)
B. henselae strains to future tests might improve the sensitivity.
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INTRODUCTION
Bartonella henselae is the causative agent of cat-
scratch disease (CSD), which usually presents as a
self-limiting lymphadenopathy. In a minority of
cases, including immunocompromised hosts,
B. henselae can cause atypical infections, such as
osteomyelitis, endocarditis or peliosis hepatis.
The prolonged painless lymphadenopathy may
mimic malignancies and tuberculosis [1,2]. Quick
and reliable conﬁrmation of CSD can prevent
unnecessary diagnostic procedures, or reveal
cases of CSD for which antibiotic treatment needs
to be considered.
For over 30 years, diagnosis of CSD has relied
on clinical criteria and skin tests [1], but the
simplicity of serology means that this approach is
now usually the ﬁrst step in the conﬁrmation of
suspected CSD [3,4]. Indirect immunoﬂuores-
cence assay (IFA) and ELISA are used for detec-
tion of anti-B. henselae antibodies in serum.
Although IFA is the technique used most widely,
IFA is more time-consuming than ELISA, and
interpretation might be less objective [5]. Previous
evaluations of serological tests reported a range of
sensitivities and speciﬁcities, depending on the
study population, deﬁnitions of CSD, and the
materials and techniques used [3,6,7]. B. henselae
is difﬁcult to culture from patients, but PCR is
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highly speciﬁc and sensitive for detecting
B. henselae DNA in pus or lymph node specimens.
The sensitivity of PCR is dependent on the target
genes and the particular patient group [3,8–12].
The main disadvantage of PCR is the need to
obtain invasive samples of pus or other relevant
tissue [10]. Although recent studies have suggest-
ed a more complex classiﬁcation of B. henselae,
two B. henselae 16S rRNA genotypes that are
associated with cases of CSD have been identiﬁed
previously [13–15]. Genotypes I (corresponding to
serotype Houston-1) and II (serotype Marseille)
can be distinguished by PCR [16]. After the
discovery of genotype II, Drancourt et al. [13]
suggested that the precise genotype involved
might inﬂuence the accuracy of serological tests,
although this has not been conﬁrmed.
In the present study, the diagnostic perform-
ance of IFA and ELISA was evaluated in patients
with a clinical presentation consistent with CSD,
conﬁrmed by PCR, and in a clinically relevant
control group with negative PCR results. A
commercially available IFA was compared with
in-house assays, and the inﬂuence of the two
different B. henselae genotypes on the sensitivity
of these serological assays was examined.
MATERIALS AND METHODS
Patient population
Material from patients in The Netherlands with suspected
B. henselae infection is sent to two national reference laborat-
ories, the National Institute of Public Health and the Environ-
ment, Bilthoven (RIVM) and the Regional Public Health
Laboratory, Tilburg (RPHL). Patients with material sent for
both B. henselae PCR and serology, with sufﬁcient serum stored
for additional testing, were selected from the laboratory
databases of both centres. The referring physicians were asked
to complete an anonymised form that provided clinical and
epidemiological data (age, gender, symptoms of disease,
duration of illness, cat contact and ﬁnal diagnosis). The
patients were divided into the study group (CSD group) and
the negative control group according to clinical data and PCR
results (Fig. 1).
CSD group. The CSD group included patients with a clinical
presentation of CSD, based on retrospective analysis of clinical
data and a PCR test positive for B. henselae. Clinical presen-
tation of CSD was deﬁned as lymphadenitis or an atypical
presentation of B. henselae infection in the absence of another
diagnosis. The combination of matching clinical data and a
positive PCR result was considered to be the reference
standard for a proven infection with B. henselae.
Control group. The control group included patients whose
material was sent for B. henselae testing, but who eventually
had a different clinical diagnosis (Table 1) and a PCR test
negative for B. henselae.
Exclusions. Exclusions included patients who did not meet the
criteria for the above two groups, or for whom insufﬁcient
clinical data concerning their diagnoses were available.
Laboratory techniques
All serum samples were analysed for B. henselae-speciﬁc IgM
and IgG antibodies by ELISA at RIVM, and by IFA at RPHL. If
two or more serum samples from one patient were obtained
(n = 16), the specimen collected nearest to the date of collection
of PCR material was analysed. Sera were stored at )20C.
IFA. In-house antigen slides for detection of IgM and IgG
antibodies to B. henselae were prepared as described previ-
ously [3]. A bacterial suspension of c. 108 CFU ⁄mL was made
from B. henselae ATCC 49882 (B. henselae type Houston-1),
grown on Columbia agar supplemented with sheep blood
5% v ⁄v. The suspension was mixed with egg yolk emulsion
Patients initially suspected of CSD with PCR result 
and serum available for retesting 
n = 171 
• Presentation consistent with CSD
• No other diagnosis
• Positive PCR 
• Diagnosis other than CSD 
consistent with symptoms
• Negative PCR 
• No clinical data (n = 32)
• PCR and/or clinical diagnosis 
not consistent with CSD (n =32)
Excluded 
n = 64
CSD group
n = 51
Control group
n = 56
Fig. 1. Subdivision of patients ini-
tially suspected of having cat-
scratch disease (CSD) on the basis
of clinical analysis and PCR tests for
Bartonella henselae, resulting in three
groups: CSD group, control group
and excluded patients.
Table 1. Clinical diagnoses in the control group (n = 56)
Diagnosis Number of patients (%)
Infection 20 (36%)
Mycobacterial (atypical) 8 (40%)
Mycobacterial (typical) 4 (20%)
Bacterial, other 7 (35%)
Viral 1 (5%)
Malignancy 21 (38%)
Hodgkin’s lymphoma 6 (30%)
Non-Hodgkin’s lymphoma 5 (25%)
Other 10 (50%)
Immunological disordera 8 (14%)
Congenital cyst ⁄ﬁstula 5 (8.9%)
Other diagnosis 2 (3.6%)
aReactive lymphadenitis in human immunodeﬁciency virus infection, rheumatoid
arthritis, systemic lupus erythematosus, sarcoidosis, autoimmune lymphoprolifer-
ative syndrome and Devic’s disease.
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50 lL ⁄mL (Unipath, Basingstoke, UK), and spotted on Teﬂon-
coated slides. The slides were air-dried for 30 min and ﬁxed in
acetone for 30 min. Sera and conjugates were diluted in
phosphate-buffered saline (PBS; pH 7.2) containing bovine
serum albumin 0.05% w ⁄v and NaN3 0.1% v ⁄v. For the
detection of IgM antibodies, sera were pre-treated with IgG
blocking solution (Incstar Corp., Stillwater, MN, USA).
The commercially available slides for detection of
B. henselae IgM (Focus Technologies, Cypress, CA, USA) are
marketed solely for in-vitro diagnostic use outside the USA.
The commercially available slides were used according to
the manufacturer’s recommendations in parallel with the
in-house prepared slides.
All IFA results were evaluated independently by two
experienced scientists, who were unaware of the clinical and
laboratory ﬁndings. Inter-observer differences never exceeded
one dilution step. In cases of disagreement (n = 11), the
opinion of an independent third scientist was considered
conclusive. The most frequently reported cut-off values, i.e.,
positivity at titres of ‡1:64 for IgG and ‡1:8 for IgM, were used
[17].
ELISA. Detection of anti-B. henselae IgM and IgG by an
in-house ELISA was based on the methods described previ-
ously by Bergmans et al. [3] and Barka et al. [18], with several
modiﬁcations to improve sensitivity. B. henselae strain
ATCC 49882 was grown on Columbia agar plates containing
sheep blood 5% v ⁄v for 7–10 days at 35C in an atmosphere
containing CO2 5% v ⁄v. Colonies were scraped from the
plates, suspended in PBS, sonicated for 30 min and stored at
)20C. Wells of microtitre plates (Polysorb; Nunc, Roskilde,
Denmark) were coated overnight at 4C with 100 lL of an
optimal dilution of the B. henselae antigen prepared in PBS.
Parallel wells were coated with PBS alone to control for non-
speciﬁc binding of serum components. After incubation, the
plates were washed twice with PBS containing Tween-20
0.05% v ⁄v and blocked with blocking reagent (Boehringer-
Ingelheim, Ingelheim, Germany) according to the manufac-
turer’s instructions. Serum dilutions (1:100) were added and
then incubated for 1 h at 37C. Plates were washed four times
between each incubation step. For the IgM assay, sera were
depleted of IgG in advance of testing with IgG-RF sorbent
(Biotest, Shirley, UK), used according to the manufacturer’s
instructions, to prevent possible inter-isotype competition.
Bound antibody was detected using horseradish-peroxidase-
labelled goat anti-human IgM (Biorad, Hercules, CA, UK) or
rabbit anti-human IgG (Dako, Glostrup, Denmark) for 1 h at
37C. Tetramethylbenzidine was used as substrate, and
colour development was stopped after 10 min with 2 M
H2SO4. The plates were read at 450 nm (second ﬁlter
690 nm). A high positive, a low positive and a negative
control serum were examined in each assay. In order to
create a highly speciﬁc test, 126 age-matched controls for a
group of PCR-positive CSD patients were used to calculate
optimal cut-off values of the IgM and IgG ELISAs. Cut-off
values were set at the average optical density (OD) for
this group, plus three times the standard deviation (SD) for
IgM, and plus two SD for IgG, to reach acceptable speciﬁcity
levels of 97% and 98% for IgM and IgG, respectively.
A serum sample was considered positive if the calculated
ratio (OD sample:cut-off value) was ‡1, which corresponded
to cut-off values of ‡0.110 OD and 0.623 OD for IgM and
IgG, respectively.
PCR. Pus aspirates and biopsy specimens from lymph nodes
were used for PCR detection of B. henselae DNA, using primers
based on the 16S rRNA gene [10]. This test was reported by
Bergmans et al. [10] to have a sensitivity of 96% in patients
with a positive skin test. If the B. henselae PCR was positive, a
16S rRNA genotype-speciﬁc PCR was performed to detect the
type I and type II genotypes [16].
Data analysis
The data were analysed using SPSS v.11.0 for Windows (SPSS
Inc., Chicago, IL, USA). Clinical and epidemiological data for
the CSD and control groups were compared using the two-
sample t-test or, when the normal distribution assumption
was not met, the Mann–Whitney U-test for continuous data,
and the chi-square test for nominal data. Sensitivity and
speciﬁcity were calculated for detection of IgG and IgM in
the IFA and ELISA tests. Receiver operating characteristic
(ROC) curves were generated for the different tests, with the
area under the curve (AUC) indicating the measure of
accuracy.
As IFA results are expressed as titres, only a certain
number of cut-off values was possible. Samples were tested
only at a 1:8 dilution for IgM, and at 1:8, 1:16, 1:32 and 1:64
dilutions for IgG. Therefore, the ROC curve of the IFA test
was angular, in contrast to the gradual line of the ELISA
with its numerical results. Thus, comparing the AUCs for
IFA and ELISA is not entirely appropriate for evaluation of
the use of ELISA and IFA for testing IgM and IgG. In order
to compare the two tests, the speciﬁcity of the ELISA was
levelled with that of the IFA. Therefore, the cut-off for the
ELISA tests was changed to attain the speciﬁcity of the IFA
at cut-off titres of 1:8 (IgM) and 1:64 (IgG). Comparison of
the sensitivity of the tests was then possible at equal
speciﬁcity by use of McNemar’s test for matched pairs for
IgM and IgG. The sensitivity of serological testing was
compared for different B. henselae genotypes. Group differ-
ences were considered to be statistically signiﬁcant if their
two-tailed p values were £0.05.
RESULTS
Patient data
Between January 2000 and June 2001, 171 patients
were selected, with a response rate of 86% to the
clinical data enquiry. According to the clinical
data and PCR results, the patients were divided
into the CSD group and the negative control
group (Fig. 1). Sixty-four patients were excluded
because of insufﬁcient or no clinical data (n = 23),
an undeﬁned diagnosis (n = 13), or a clinical
presentation of CSD but a negative PCR result
(n = 28).
CSD group. The median age of the CSD patients
was 27.0 years (n = 51; range 1–83 years), which
was not signiﬁcantly different from that of the
control group (median 31.2 years, range 1–81
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years). No statistically signiﬁcant difference
in gender was found between the CSD group
(71% male) and the control group (57% male).
In the CSD group, most (96%) patients present-
ed with typical CSD with lymphadenitis. In 45%
of these cases, the lymphadenitis was axillary,
with 31% being in the neck region. Two patients
presented with atypical CSD (multifocal osteo-
myelitis and endocarditis) without lymphadeni-
tis. Information concerning contact with cats was
available for 33 CSD cases, with 88% reporting
cat contact in the 3-month period before the start
of symptoms, and 12% reporting no cat contact.
Control group. Patients in the control group
(n = 56) were diagnosed with malignancies
(38%), with infections other than CSD (36%),
and with other clinical conditions (26%) (Table 1).
In the control group, 87% of patients had lymph-
adenopathy, with the neck region being the most
frequent (59%) localisation.
The period between collection of PCR and serum
samples was <1 week for 47% of cases, and
>10 weeks for 21% of cases, which did not differ
signiﬁcantly from the control group. To eliminate
the possible inﬂuence of a large interval, the data
were re-analysed after excluding the cases with
an interval of >60 days (n = 18), but no change in
the results was observed (data not shown).
Serology
The results obtained are summarised in Table 2.
In-house IFA. Speciﬁcities of 93% for IgM and
82% for IgG were reached with the in-house IFA,
with sensitivities of 53% and 67%, respectively.
Combining in-house IgM and IgG (deﬁning posi-
tivity as a positive IgM and ⁄ or a positive IgG)
increased the sensitivity to 86%, at the expense of
a reduction in speciﬁcity to 77%.
Commercial IFA. Three of the 51 CSD patients
tested positive with the commercial IFA IgM
slides, corresponding to a sensitivity of 6%. All
samples from the control group tested negative
(speciﬁcity 100%).
In-house ELISA. The in-house ELISA showed a
speciﬁcity of 91% for both IgM and IgG, and
sensitivities of 65% and 28% for IgM and IgG,
respectively. Combining the IgM and IgG results
in the ELISA improved the sensitivity (77%), but
reduced the speciﬁcity (82%).
Duration of disease
The date of the ﬁrst clinical symptoms was known
for 41 patients (44 sera) in the CSD group. The
period between the ﬁrst clinical symptoms and the
time of blood sampling did not signiﬁcantly inﬂu-
ence the sensitivity or speciﬁcity of the assays,
except for IFA IgM, which had a better sensitivity
with blood samples taken within 6 weeks of the
ﬁrst symptoms. Despite the small numbers, Fig. 2
shows a pattern in serological positivity. In IFA, the
IgM positivity decreased after 8 weeks, while IgG
positivity peaked at 6–8 weeks. Such a pattern was
not clear with the ELISAs, mainly because of the
low sensitivity of the IgG ELISA.
Comparison of IFA and ELISA
IgM tests showed 86% concordance between the
ELISA and IFA results. For IgG, concordance was
67%, mainly because of the difference in sensi-
tivity. The ROC curves demonstrate that the IgG
ELISA was poor at discriminating CSD patients
from the control group, with an AUC of 0.67
(Fig. 3). The IgM and IgG IFAs performed better
(AUC 0.73 and 0.79, respectively), and the IgM
ELISA performed best (AUC 0.85). At the point
where speciﬁcity is c. 92%, corresponding to the
Table 2. Results with Bartonella henselae immunoﬂuorescence assay (IFA) and ELISA for cat-scratch disease (CSD) patients
(n = 51) and the control group (n = 56), together with positive and negative predictive values
IFA commercial assay IFA in-house assay ELISA in-house assay
IgM IgM IgG IgM IgG
Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative
CSD group n (%) 3 (6) 48 (94) 27 (53) 24 (47) 34 (67) 17 (33) 33 (65) 18 (35) 14 (28) 37 (73)
Control group n (%) 0 (0) 56 (100) 4 (7) 52 (93) 10 (18) 46 (82) 5 (9) 51 (91) 5 (9) 51 (91)
Predictive value (%) 100 54 87 68 77 73 87 74 74 58
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cut-offs used in this study, the curves of these last
three tests were nearly superimposed.
In order to compare the sensitivities of the IFA
and ELISA, the ELISA cut-off was changed to
meet the same speciﬁcity as the IFA test. The
speciﬁcity of the IgM IFA (cut-off 1:8) was 92.9%,
which was also met in the ELISA after shifting the
ELISA cut-off value to 4.89 SD. At this point, the
sensitivity of the IgM ELISA (49%) did not differ
signiﬁcantly from that of the IFA (53%). For the
IgG tests, equal speciﬁcity (82%) was reached at a
cut-off of 1:64 (IFA) and 1.78 SD (ELISA). With
this cut-off, IgG sensitivity was signiﬁcantly
higher for the IgG IFA (82.1%) than for the IgG
ELISA (29.4%) (p 0.003). The ROC curve illus-
trates that the commercially available IgM IFA
did not discriminate well, with an AUC of 0.53.
B. henselae genotyping
All lymph node or pus specimens from the
patients in the CSD group (n = 51) were retested
with a PCR that ampliﬁed a genotype-speciﬁc
185-bp 16S rRNA fragment. Four samples were
not included in this analysis, either because the
DNA concentration was too low (n = 3), or
because genotypes I and II were both identiﬁed
(n = 1; possible co-infection). Genotype I was
identiﬁed in 32 (63%) lymph node samples and
genotype II in 15 (29%) samples. Table 3 shows
that the sensitivity of the serological tests was
higher for type I than for type II B. henselae, but
this was only statistically signiﬁcant for the IgG
ELISA (p 0.028).
DISCUSSION
The present study evaluated the diagnostic per-
formance of B. henselae-speciﬁc IgM and IgG IFAs
and ELISAs, using a group of patients with
proven CSD (clinical diagnosis conﬁrmed by
PCR) and a control group of patients with similar
symptoms, but with other conﬁrmed diagnoses
and PCR results negative for B. henselae. In-house
IgM assays showed a low sensitivity (IFA 53%,
ELISA 65%) with a high speciﬁcity (IFA 93%,
ELISA 91%). IgG assays were more sensitive in
IFA (67%) than in ELISA (28%), with speciﬁcities
of 82% and 91%, respectively. Two cases without
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Fig. 2. Seropositivity with (a) in-house immunoﬂuores-
cence assay (IFA) and (b) ELISA in relation to the duration
of disease. The percentage of positive sera (n = 44) by IFA
and ELISA is shown for Bartonella henselae IgG and IgM in
relation to duration of the disease in weeks. The numbers
of sera are 11, 11, seven, ﬁve, four and six, respectively, for
each pair of bars.
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Fig. 3. Receiver operating characteristic curves for sero-
logical testing of Bartonella henselae infection in patients
suspected clinically of having cat-scratch disease. Areas
under the curve (95% CI) are 0.85 (0.77–0.92) and 0.67
(0.57–0.77) for IgM and IgGs ELISAs, and 0.73 (0.63–0.83)
and 0.79 (0.71–0.89) for in-house IgM and IgG immuno-
ﬂuorescence assays (IFAs), respectively. The area under
the curve for the commercially available IgM IFA is 0.53
(0.42–0.64).
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lymphadenopathy were included in the CSD
group. One patient presented with multifocal
osteomyelitis, as described by de Kort et al. [19],
while the other had B. henselae endocarditis,
which usually presents as a fever of unknown
origin without lymphadenopathy in immuno-
compromised patients or in patients with a pre-
existing cardiac defect. Although it is debatable
whether B. henselae endocarditis should be con-
sidered as atypical CSD, it is believed that the
inclusion of this patient did not ﬂaw the overall
analysis.
Compared with other reports, relatively low
speciﬁcities were achieved, caused by a high
seroprevalence in the control group. This could be
explained in several ways. The controls, all of
whom were diagnosed with diseases other than
CSD, could still have had a concurrent B. henselae
infection. Rolain et al. [20] described mycobact-
eriosis in 4.2% and neoplasm in 1.2% of proven
CSD patients (n = 245). Negative PCR results may
have been caused by a delay in sample taking,
reduced DNA availability, or the limited sensi-
tivity of the assay (78–100%) [3,10,12].
The IgG results positive for Bartonella in the
control group (seroprevalence 9–18%) may reﬂect
past exposure to B. henselae, as IgG remains
positive long after infection [3,5]. Although sero-
logical cross-reactivity with B. henselae has only
been reported for Bartonella quintana and Coxiella
burnetti [21], cross-reactivity with other micro-
organisms is not unlikely [4,8]. In clinical practice,
tests for diagnosing CSD need a high speciﬁcity,
as potentially lethal diseases, e.g., malignancies
and tuberculosis, can be missed in cases in which
CSD is diagnosed incorrectly [7]. Given the high
seroprevalence and low sensitivity of testing for
anti-B. henselae IgG (especially by ELISA), IgG
testing appears to be of no additional value in
diagnosing acute CSD.
Despite the low numbers, it was conﬁrmed that
IgM antibodies are present predominantly in the
early phase of disease, while IgG antibody titres
increase subsequently [3,5,22,23]. IgM sensitivity
was optimal in the ﬁrst 6 weeks after onset of
symptoms. Earlier reports have described vari-
able patterns of antibody kinetics, but often with
an unknown duration of the disease at the time of
sample taking [3,5,22,23]. Metzkor-Cotter et al. [5]
analysed ELISA antibody kinetics in 98 patients
with CSD symptoms for 1–52 weeks, with a mean
serological follow-up of 35 weeks (range 2–211
weeks), and revealed that IgM seropositivity
disappeared within 3 months in 96% of the
patients, while IgG titres may remain positive
for >2 years after the onset of disease. The present
study suggests that serological conﬁrmation of
CSD is best performed 6–8 weeks after the onset
of disease. In patients with suspected CSD and
negative serology, a B. henselae PCR with relevant
material should be performed because of the low
sensitivity of serological testing [3,11].
It is difﬁcult to compare the present results
with earlier ﬁndings, because of the different
study populations and deﬁnitions of CSD. Var-
ious materials and techniques have been evalu-
ated, e.g., different commercially available vs.
in-house IFAs or ELISAs, detection of IgM or IgG,
and the use of different cut-off values [3–7,10].
However, Bergmans et al. [3] reported sensitivi-
ties for IgM of 50% (IFA) and 71% (ELISA), and
of 81% (ELISA), in PCR-positive patients, but as
in the present study, a low sensitivity for IgG
(9.5% ELISA, 41% IFA). Giladi et al. [6] reported
that an in-house ELISA, using the same cut-off
values as the present study, had sensitivities for
IgM and IgG of 48% and 77%, and speciﬁcities of
100% and 94%, respectively.
Comparison of serological tests from different
laboratories is also complicated by the lack of
standardisation. Therefore, the in-house IgM IFA
was compared with a commercially available IgM
IFA (Focus Technologies). The product informa-
tion brochure reported a speciﬁcity of 100%
(tested in 75 USA blood donors) and a sensitivity
of 41.5% in 94 CSD patients with lymphadenop-
athy and cat exposure. However, in the present
study, this test had a sensitivity of only 6%. In an
earlier report, Maurin et al. [24] compared the
Focus Technologies IgM and IgG IFAs with an in-
house IFA. In a group of 68 French CSD patients
(with cat contact and positive PCR results), a
Table 3. Sensitivity of serological tests in relation to
Bartonella henselae genotype
Serological
test
Genotype I-positive
sera (n = 32)
Genotype II-positive
sera (n = 15) p
IFA
IgM 66% 40% 0.10
IgG 69% 67% 0.89
ELISA
IgM 75% 53% 0.14
IgG 38% 7% 0.028
aChi-square test.
IFA, immunoﬂuorescence assay.
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sensitivity of 1.5% (1 ⁄ 68) was found for the
commercial IgM test, with a speciﬁcity of 100%
in healthy blood donors (n = 40). The in-house
IgM IFA performed similarly, with a sensitivity of
3% (2 ⁄ 68) at a cut-off titre of £1:20. The IgG IFA
sensitivity was higher for the commercial test
(91%) than for the in-house assay (53%, p <0001),
with a speciﬁcity of 100% in healthy blood donors
and of 70% in patients with tuberculosis (n = 10).
Reports concerning other commercially avail-
able tests illustrate the range in performance of
serological tests for B. henselae. Zbinden et al. [25]
reported that two commercial IFAs with agar-
derived B. henselae showed IgG positivity with
45–52% of healthy controls (n = 58), while two
other IFAs with cell-associated B. henselae were
positive in only 3.4–5.2% of cases. Sander et al. [7]
evaluated two IFAs, one based on larynx carcinoma
cells infected with B. henselae (type Houston-1) and
one based on Vero cells infected with B. henselae
and B. quintana. In a group of 42 CSD patients (20
PCR-positive) and 100–270 healthy controls, IgM
tests were 88–95% sensitive and 64–86% speciﬁc,
while IgG tests were 93–100% sensitive and
70–73% speciﬁc. An antibody seroprevalence to
B. henselae of 30% was measured in healthy
German individuals, irrespective of cat ownership.
Whether the poor performance of the commer-
cial IgM test in the present study, as well as in the
French study, was caused by a failure in slide
preparation or by the characteristics of the study
population remains unclear [24]. Another explan-
ation might be the inﬂuence of different geno-
types on the sensitivity, as shown in the present
study. Although the number of patients was too
low to achieve statistical signiﬁcance (except for
the IgG ELISA), infection with a genotype I strain
seemed to be detected more easily by current
serological techniques than were infections with
type II strains. Possibly an infection with a
genotype I strain triggers a higher and longer-
lasting antibody response than that obtained with
genotype II strains, and is therefore detected more
easily. However, a more plausible explanation is
the use of the homologous ATCC 49882 (geno-
type I) B. henselae strain in the IFA and ELISA,
which might give a lower or negative serological
reactions in patients infected by genotype II [13].
Since c. 25% of Dutch CSD cases are not infected
with B. henselae type I, the use of locally isolated
16S type I and type II B. henselae strains in
serological assays may improve performance [16].
In conclusion, improving serological tests for
diagnosing CSD remains a challenge, as no ideal
serological test has yet been described. In this
population, the detection of B. henselae IgM anti-
bodies by IFA or ELISA in patients suspected of
having CSD is highly conﬁrmative for the diag-
nosis, with a positive predictive value of 87%. IgG
tests appear to be of limited use, as sensitivity and
speciﬁcity will be low in populations with a high
seroprevalence. Given the low sensitivity of the
serological assays, PCR analysis for B. henselae
should be considered for patients with suspected
CSD and negative serology. As the sensitivity of
serological testing seems to depend on the
B. henselae genotype causing the infection, the
inclusion of several locally isolated strains might
improve the performance of the tests.
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